More on crizotinib.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases.Translational oncology · 2019
   Article
2. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.BMC cancer · 2018
   Article
3. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2016
   Article
4. Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.Oncotarget · 2016
   Article
5. Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2016
   Review
6. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.Translational lung cancer research · 2014
   Review
7. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.OncoTargets and therapy · 2014
   Review
8. Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer.Virchows Archiv : an international journal of pathology · 2013
   Article
9. Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.World journal of clinical oncology · 2011
   Article

Corrections and comments

• Comment on
  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.2010

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as